Table 4.
Transfusion of platelets capable of becoming activated prevents death and ameliorates hemorrhagic anemia
| Treatment | n | Platelets, 103/μl | Survival, % | Hct, % |
|---|---|---|---|---|
| NaCl | 5 | 1,009 ± 45 | 100 | 46.6 ± 4.2 |
| α-Irr + LCMV | 8 | 121 ± 36 | 100 | 33.9 ± 3.9 |
| α-PLT + LCMV | 8 | 3 ± 1 | 37.5 | 9.9 ± 3.4 |
| α-PLT + LCMV + TKK PLT | 8 | 54 ± 12 | 100 | 24.6 ± 2.6 |
| α-PLT + LCMV + TKK PLT PGE1 | 5 | 271 ± 13 | 40 | 11.6 ± 1.7 |
| α-PLT + TKK PLT | 5 | 263 ± 36 | 100 | 46.4 ± 3.2 |
B10D2 mice were injected with α-Irr or α-PLT 3 h before LCMV Arm infection (106 pfu per mouse). Three days after infection, one group of α-PLT-treated mice received 6 × 108 TKK-PLT, and another group received 6 × 108 TKK-PLT pretreated with PGE1. Mice receiving NaCl or α-PLT and 6 × 108 TKK-PLT but no LCMV served as controls. Platelet counts (mean ± SD) were assessed individually 1 day after transfusion. Survival and Hct (mean ± SD) were assessed individually 6 days after infection.